A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
A phase 3 trial of Inavolisib in HER2-positive breast cancer, run by Hoffmann-La Roche, now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT05894239 by Hoffmann-La Roche, with 230 participants planned, started 2023-09-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy and Optional Endocrine Therapy of Investigator's Choice.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Flatiron Health (Roche), HER2-positive breast cancer and the tag pipeline.
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Shares Flatiron Health (Roche) and the tag pipeline.
- TrialA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Shares Flatiron Health (Roche) and the tag pipeline.